ÍøºìºÚÁÏ

Skip to main content

James Wymer, MD, FAAN : Research

Neuromuscular Medicine Specialist

Photo of James Wymer

Research at a glance

Top areas of exploration

  • Amyotrophic Lateral Sclerosis , 33 publications
  • Deglutition Disorders , 11 publications
  • Deglutition , 10 publications
  • Disease Progression , 7 publications

Research activity

56 publications

1,494 citations

Why is this important?

Active clinical trials

LUMINA

This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).

Investigator
James Wymer
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
ALS Imaging
Investigator
James Wymer
Status
Accepting Candidates

My publications

56 publications

2025

Risk prediction for ALS using semi-competing risk models with applications to the ALS Natural History Consortium dataset.

Amyotrophic lateral sclerosis & frontotemporal degeneration

•

2025

Time-to-event prediction in ALS using a landmark modeling approach, using the ALS Natural History Consortium dataset.

Amyotrophic lateral sclerosis & frontotemporal degeneration

•

2025

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

JAMA neurology

•

2025

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

JAMA

•

2025

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

JAMA network open

•